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Objectives This study sought to examine whether suppressing premature ventricular contractions (PVC) using radiofre-
quency ablation improves effectiveness of the cardiac resynchronization therapy (CRT) in nonresponders.
Background CRT is an effective strategy for drug refractory congestive heart failure. However, one-third of patients with CRT
do not respond clinically, and the causes for nonresponse are poorly understood. Whether frequent PVC contrib-
ute to CRT nonresponse remains unknown.
Methods In this multicenter study, CRT nonresponders with 10,000 PVC in 24 h who underwent PVC ablation were en-
rolled from a prospective database.
Results Sixty-five subjects (age 66.6  12.4 years, 78% men, QRS duration of 155  18 ms) had radiofrequency abla-
tion of PVC from 76 foci. Acute and long-term success rates of ablation were 91% and 88% in 12  4 months of
follow-up. There was significant improvement in left ventricular (LV) ejection fraction (26.2  5.5% to 32.7 
6.7 %, p  0.001), LV end-systolic diameter (5.93  0.55 cm to 5.62  0.32 cm, p  0.001), LV end-diastolic
diameter (6.83  0.83 cm to 6.51  0.91 cm, p  0.001), LV end-systolic volume (178  72 to 145  23 ml,
p  0.001), LV end-diastolic volume (242  85 ml to 212  63 ml, p  0.001), and median New York Heart
Association functional class (3.0 to 2.0, p  0.001). Modeling of pre-ablation PVC burden revealed an improve-
ment in ejection fraction when the pre-ablation PVC burden was 22% in 24 h.
Conclusions Frequent PVC is an uncommon yet significant cause of CRT nonresponse. Radiofrequency ablation of PVC foci
improves LV function and New York Heart Association class and promotes reverse remodeling in CRT nonre-
sponders. PVC ablation may be used to enhance CRT efficacy in nonresponders with significant PVC
burden. (J Am Coll Cardiol 2012;60:1531–9) © 2012 by the American College of Cardiology FoundationCardiac resynchronization therapy (CRT) is an effective and
established treatment for patients with drug-refractory con-
gestive heart failure and significant electromechanical delay.
Several studies have clearly established a beneficial role of
CRT in improving the functional status and hemodynamic
and echocardiographic parameters in heart failure patients
(1–6). Improvement in functional status has been used as
the direct marker of response to CRT in previous clinical
studies (7). Change in ejection fraction, end-systolic vol-
ume, degree of mitral regurgitation, and cardiac output have
been used as surrogate markers for response to CRT using
echocardiographic data (8–10). However, it is also known
that nearly 30% (range 18% to 52%) (11,12) of patients who
meet the criteria for implantation will not respond to CRT.
Considering the complexity and the economic impact of
CRT, it is important to maximize the number of responders
to this approach. In this regard, studies have shown the
importance of effective biventricular capture in CRT re-
sponders (13), and it is predictable that subjects with high
premature ventricular contraction (PVC) burden will have
decreased effective biventricular pacing. The presence of
fusion or pseudofusion beats due to high PVC burden can
also decrease the response to CRT (14). This could hinder
the ventricular reverse remodeling accomplished by restora-
tion of mechanical and electrical resynchronization through
CRT (15).
A bidirectional nature of cause-and-effect relationship
between PVC and cardiomyopathy has been proposed in
the past (16). Studies have shown that gradual deteriorationof ejection fraction can be seen in subjects with normal
systolic function who have frequent PVC (17). High PVC
burden is a significant but less known cause of heart failure
(18) and carries a poor prognosis (19). Improvement in
systolic function after PVC suppression has been reported in
subjects with high PVC burden in the past (20–22). Earlier
studies have shown that patients who have a positive
response to CRT often experience a reduction in ventricular
arrhythmia burden (23–25). The effect of PVC ablation in
subjects who are considered nonresponders to CRT has
been reported in case reports (26), but it has not been
investigated in a large study.
Methods
This was a prospective, multicenter, nonrandomized obser-
vational study that assessed the effect of PVC ablation in
consecutive subjects considered nonresponders to CRT with
high PVC burden. All subjects who underwent CRT
implantation between January 2007 and June 2010 were
screened for the study. Any patient who had received or
upgraded to a clinically indicated biventricular pacemaker or
defibrillator was considered for this study. Patients were
eligible if they had5% improvement in the left ventricular
ejection fraction (LVEF) and or LV end-systolic volume of
10% with no associated improvement in clinical status 1
year after CRT implantation (27). These patients were
considered nonresponders. All subjects had echocardiogra-
phy within 4 weeks prior to PVC ablation and 6 months
after ablation to assess LV function and LV dimensions.
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October 16, 2012:1531–9 PVC Ablation in CRT NonrespondersFrequent PVC were considered a potential cause of non-
CRT response and were further screened. Those patients
who had 10,000 PVC in a 24-h period documented by a
olter monitoring were considered to have a significant
VC burden and were thus enrolled in the study (28).
atients who had sustained ventricular tachycardia requiring
ntitachycardia pacing or shock therapy were excluded.
imilarly, patients with atrial fibrillation burden of more
han 1% were also excluded from the study. Beta-blocker
herapy was maximized as tolerated by the patient once
atients with significant clinical burden of frequent PVC
ere identified. Antiarrhythmic drugs were used at the
iscretion of the treating physician.
VC ablation. All patients who met the inclusion criteria
ere offered the PVC ablation. All subjects were informed
f the benefits and risks of the procedure and consented
nder direction of the respective institutional review boards
nd human subject committees.
Eligible patients underwent electrophysiology study and
adiofrequency ablation (RFA) of the PVC. If 1 PVC
ocus was identified, then an attempt was made to ablate all
orphologies. An attempt was made to assess the site of
rigin based on the surface 12-lead electrocardiogram or
2-lead Holter prior to the ablation. The right ventricle was
apped via the standard femoral approach and the LV was
apped via a transseptal or retrograde aortic approach.
picardial access was obtained as deemed necessary by the
perator. The patient was anticoagulated with unfraction-
ted heparin for activated clotting time of 300 to 350 s for
ll left-sided procedures. Remote magnetic-guided naviga-
Figure 1 Voltage and Activation Map in a Patient Undergoing P
(A) The earliest site of activation along the postero-basal septum on Carto linear
(B) Voltage map showing scar along the postero-basal septal distribution of the leion (Stereotaxis, St. Louis, Mis-
ouri) was used for mapping and
blation based on operator choice.
n addition to the standard diag-
ostic catheters, 3-dimensional
lectroanatomic mapping (Carto,
iosense Webster Inc., Diamond
ar, California; or NavX/Array,
t. Jude Medical Inc., St. Paul,
innesota) was used in all proce-
ures (Fig. 1). Intracardiac echo-
ardiography (Acunav, Siemens,
ountain View, California) was
sed in all patients to guide trans-
eptal and epicardial accesses and
lso to monitor catheter location
nd pericardial effusion. RFA was
erformed through an open irri-
ated ablation catheter (Thermocool Celsius or Navistar,
iosense Webster Inc.). Anatomic and activation mapping
ere performed simultaneously. The earliest activation
oint that matched pace mapping was targeted for ablation.
ace mapping was performed in all cases to confirm the site
f origin of the PVC. Voltages were defined as follows:
0.5 mV as scar; 0.5 to 1.5 mV as the border zone. The vast
ajority of patients underwent the procedure under conscious
edation with only a few requiring general anesthesia. Intrave-
ous isoproterenol (up to 10 g/min for 10 min), caffeine (250
mg over 20 min), calcium chloride (1 g over 10 min), and
phenylephrine (5 g/kg for 10 min) were also infused as
Abbreviations
and Acronyms
BiV  biventricular
CRT  cardiac
resynchronization therapy
EF  ejection fraction
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
PVC  premature
ventricular contraction(s)
RFA  radiofrequency
ablation
blation
ion time map (Biosense Webster Inc., Diamond Bar, California) is shown.
ricle corresponding to the premature ventricular contraction (PVC) focus.VC A
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PVC Ablation in CRT Nonresponders October 16, 2012:1531–9deemed necessary for induction of ectopy during the procedure
if there was paucity of PVC impeding activation mapping. If
PVC remained infrequent, pace-mapping was performed at a
pacing cycle length that matched the coupling interval of the
spontaneous ventricular ectopy (29). Complete abatement of
clinical PVC after RFA was targeted whenever possible.
Patients were monitored for a minimum of 30 min after the
last radiofrequency application to ensure complete abatement
of the ventricular ectopy. If 1 PVC focus was seen, then the
most frequent one was targeted first followed by the infrequent
ones. All patients were monitored overnight on the day of the
procedure and were discharged the following day.
Assessment of LV function and dimensions. A baseline
echocardiogram was performed within a 4-week window
before RFA. A follow-up echocardiogram was performed to
assess LV function and dimensions at 6 months after the
procedure. Echocardiograms were assessed by 2 independent
echocardiographers who were blinded to the study and outcome
of the ablation procedure. LVEF was calculated by Simpson
formula when 2 consecutive biventricular paced beats were pres-
ent, using the second paced beat for analysis of the ejection
fraction to avoid post-extrasystolic potentiation of LV function.
Assessment of PVC burden. To assess clinical response, all
atients were monitored using 24-h Holter telemetry at 48 h,
months, and 6 months after ablation. The PVC burden
oted on the CRT device was also used to confirm the results
rom Holter telemetry. If the PVC burden was 1,000 per
4-h period, the procedure was considered to be successful.
tatistical analysis. SPSS Statistical Package (version 16.0,
PSS Inc., Chicago, Illinois) was used for statistical analysis.
ontinuous data were summarized by mean SD, categorical by
ercentages, and ordinal by median and interquartile range.
Post-PVC ablation continuous clinical and echocardio-
raphic data was compared to pre-ablation values using the
aired t test, and ordinal data was compared using the
ilcoxon signed rank test. Pre-ablation PVC burden
roups (i.e., 22 and 22) were compared using Student
ndependent t test or the Mann-Whitney U test as appro-
riate for continuous or ordinal data. Repeated measure
nalysis was performed using the general linear model
rocedure to test significant analysis of variance with post
oc Bonferroni testing was used for multiple comparisons of
cho parameters and Kruskal-Wallis was used for New York
eart Association (NYHA) functional class. A linear model
as used to identify the point estimate for pre-ablation
iventricular pacing percentage corresponding to zero EF
mprovement. Results are shown graphically along with
ignificant correlation coefficients. A p value 0.05 was
onsidered significant.
esults
aseline characteristics. A total of 2,034 patients who had
RT were screened. Of these patients, 509 (25%) were
onsidered nonresponders. Among the nonresponders, 13%
65 of 509) met the criteria of significant PVC burden (age:7  12 years, men: women: 3.6:1, QRS duration of 155 
8 ms). Hypertension was present in 65% of these patients
nd diabetes in 52%. Ischemic cardiomyopathy was present
n 35%. The most common QRS morphology was left
undle branch block, which was present in 59%. Other
linical and demographic characteristics are outlined in
able 1.
The average time from CRT implant to PVC ablation
as 14.8  6.1 months.
rocedural characteristics. Seventy-six foci were ablated
n 65 patients. The vast majority had a single focus (86%)
ith the remaining patients having 2 foci. Carto was used
Baseline CharacteristicsTable 1 Baseline Characteristics
Age, yrs 66.6 12.4
Sex, M/F 3.6/1.0
CRT device type
CRTD 61 (93.8%)
CRTP 4 (6.2)
Median NYHA functional class 3.0
Cardiomyopathy type
DCM 42 (64.6)
ICM 23 (35.4)
QRS width, ms 155.2 17.9
Underlying QRS morphology
IVCD 7 (10.8)
LBBB 38 (58.5)
Paced 11 (16.9)
RBBB 9 (13.8)
Comorbidities
Diabetes 34 (52.3)
HTN 42 (64.6)
Hyperlipidemia 38 (58.5)
CAD 29 (44.6)
Chronic renal insufficiency (Cr 1.5) 11 (16.9)
Ventricular fibrillation 21 (32.3)
Medications
Beta blocker 65 (100)
ACE inhibitor 62 (95.4)
Antiarrhythmic drugs 9 (13.8)
Echo parameters
LVEF, % 26.2 5.5
LVESD, cm 5.93 0.55
LVEDD, cm 6.83 0.93
LVESV, ml 178 72
LVEDV, ml 242 85
Percentage of pre-ablation PVC burden
10%–20% 27 (41.5)
20.1%–30% 20 (30.8)
30.1%–40% 9 (13.8)
40.1% 9 (13.8)
Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme; CAD  coronary artery disease; CRT  cardiac resyn-
hronization therapy; CRTD  cardiac resynchronization therapy-defibrillator; CRTP  cardiac
esynchronization therapy-pacemaker; DCM  dilated cardiomyopathy; HTN  hypertension;
CM  ischemic cardiomyopathy; IVCD  intraventricular conduction defect; LBBB  left bundle
branch block; LVEDD  left ventricular end-diastolic diameter; LVEDV  left ventricular end-
diastolic volume; LVEF  left ventricular ejection fraction; LVESD  left ventricular end-systolic
diameter; LVESV  left ventricular end-systolic volume; NYHA  New York Heart Association;
PVC  premature ventricular contraction; RBBB  right bundle branch block.
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October 16, 2012:1531–9 PVC Ablation in CRT Nonrespondersmore frequently than NavX was (78.5% vs. 21.5%). Remote
magnetic navigation was used in 28% of patients. The mean
procedural duration was 157 45 min. Sixty-nine of the 76
(90.8%) foci was successfully ablated (Table 2). LV was the
most common source of the PVC (75%) with the right
ventricle being the source of ectopy in 25%. Epicardial focus
was ablated in 4 (6%) patients. Submitral annulus (29%) and
right ventricular outflow tract (16%) were the most common
sites of origin. The distribution of other sites of origin is
outlined in Table 3.
Follow-up and procedural outcomes. Acute success was
seen in 91% of patients with only 2 patients experiencing
procedure-related complications (transient ischemic attack
in 1 and pericardial tamponade in the other). During a mean
follow-up period of 12  4 months, the procedural success
remained high at 88% (PVC burden 1,000 per 24 h). In
3% (n  2) who had acute success but late recurrence, there
was recurrence of PVC and 1 underwent repeat ablation
while the other was treated with antiarrhythmic drugs.
There were no deaths or any other major comorbid events
during the follow-up period.
Effect of ablation on echo parameters and NYHA
class. Follow-up echocardiography 6 months after ablation
revealed CRT response with improvements in mean LVEF
(26.2  5.5% to 32.7  6.7%, p  0.001), LV end-systolic
iameter (5.83  0.55 cm to 5.62  0.32 cm, p  0.001),
V end-diastolic diameter (6.83  0.83 cm to 6.51  0.91
m, p  0.001), LV end-systolic volume (178  72 ml to
45  23 ml, p  0.001), LV end-diastolic volume (242 
5 ml to 212 63 ml, p 0.001), and median NYHA class
3.0 to 2.0, p  0.001) (Table 4).
orrelation between severity of PVC burden and CRT
esponse after PVC ablation. The pre-ablation PVC bur-
en was stratified into 3 categories based on PVC frequency
Procedural CharacteristicsTable 2 Procedural Characteristics
Intraprocedural Variable
Number of clinical PVC
1 56 (86.2)
2 7 (10.8)
3 2 (3.1)
Type of 3D electroanatomic mapping
Carto 51 (78.5)
NavX 14 (21.5)
Remote magnetic-guided navigation 18 (27.7)
Intracardiac echocardiography 65 (100)
Mean procedure time, min 157.2 44.8
Procedural complications 2 (3.0)
Tamponade 1 (1.5)
TIA 1 (1.5)
Acute successful PVC ablation
Yes 69 (90.8)
No 7 (9.2)
Values are n (%) or mean  SD. Carto is a product of Biosense Webster Inc. (Diamond Bar,
California), and NavX is a product of St. Jude Medical Inc. (St. Paul, Minnesota).
3D 3-dimensional; PVC premature ventricular contraction; TIA transient ischemic attack.s a percentage of all beats: 10% to 20%, 20.1% to 30%,30%. The resulting average improvement in echo param-
ters is shown for each category in Table 5. The greatest
hange was seen in those patients who had the highest
ercentage of pre-ablation PVC burden (30%) (Table 5).
odeling of the percentage of pre-ablation PVC burden on
he improvement in EF found that EF improved (0%)
hen the percentage of pre-ablation PVC burden was
reater than 14.3% and for a clinically significant improve-
ent in EF the pre-ablation PVC burden was 22% (Fig. 2).
he difference in improvement in echo parameters and
YHA class between patients with a pre-ablation PVC
urden of 22 vs. 22% is shown in Table 6.
ffect of PVC ablation on biventricular pacing. The
ean biventricular pacing frequency (expressed as a percent-
ge) before PVC ablation was 76  12% (range 37% to
0%). After ablation, the mean biventricular (BiV) pacing
requency improved significantly to 98  2% (p  0.001,
ange 96% to 100%). Because the percentage of BiV pacing
requency was inversely correlated to the PVC burden, there
as an inverse correlation between the pre-ablation BiV
acing frequency and the degree of improvement in LVEF
Fig. 3).
ffects of turning off CRT following successful PVC
blation. A clinical decision was made in a subset of 25
atients to turn off BiV pacing 6 months after successful
Site of Origin of PVCsTable 3 Site of Origin of PVCs
Left ventricle
LV—submitral annulus 22 (28.94)
LV—mid posterior 4 (5.26)
LV— apex 4 (5.26)
LV—distal posterolateral 4 (5.26)
LV—distal posterior 3 (3.95)
LV—outflow tract 2 (2.63)
LV—posterior papillary muscle 2 (2.63)
LV—left aortic cusp 2 (2.63)
LV—distal left posterior fascicle 2 (2.63)
LV—aortomitral continuity 2 (2.63)
LV—right aortic cusp 1 (1.32)
Epicardial LV—basal posterolateral
(coronary sinus access)
1 (1.32)
Epicardial LV—mid anterior 1 (1.32)
Epicardial LV—subapical 1 (1.32)
Epicardial LV—apex 1 (1.32)
LV—mid anterior 2 (2.63)
LV—distal posterior septal 1 (1.32)
LV—distal left anterior fascicle 1 (1.32)
LV—distal anteroseptal 1 (1.32)
Right ventricle
RV—outflow tract 12 (15.78)
RV—posterior sub-tricuspid 2 (2.63)
RV—parahisian 2 (2.63)
RV—distal septum 1 (1.32)
RV—free wall 1 (1.32)
RV—apex 1 (1.32)
Total 76 (100.0)RV  right ventricle; other abbreviations as in Tables 1 and 2.
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PVC Ablation in CRT Nonresponders October 16, 2012:1531–9ablation of the PVC to assess the true impact of PVC
ablation on LV function. The CRT was off for 6 months
and patients’ clinical status along with echo parameters were
reassessed. The echocardiography parameters and NYHA
class of these patients (Table 7) show that after the CRT
was turned off, the EF and LV systolic and diastolic
diameters and volumes returned to the pre-ablation values
in these patients. These data indicate the importance of
CRT in LV remodeling and suggest that the therapeutic
benefits of PVC ablation were largely related to improve-
ment in BiV pacing in these patients.
Differences between responders and nonresponders after
PVC ablation. About 34% (n  22) of patients who had
he PVC ablation did not respond (5% improvement in
VEF from post-CRT to post-ablation). Table 8 describes
hese differences between the post-PVC ablation responders
nd nonresponders. Responders had significantly higher
VC burden (28.7 12.2 vs. 16.2 5.0, p 0.001), lower
pre-ablation BiV pacing (71.3  12.2 vs. 83.8  5.0, p 
0.001), and a significantly higher post-ablation LVEF
(35.1  5.5 vs. 27.9  6.4, p  0.001).
Discussion
Salient findings. Our results show that: 1) high PVC
burden is a potential cause of CRT nonresponse; 2) RFA of
the PVC focus improves LVEF, LV dimensions, and
NYHA functional class in CRT nonresponders; 3) the gains
in LV function and NYHA class are directly proportional to
the pre-ablation PVC burden; 4) a pre-ablation PVC
Change in Various Echo Parameters Before andTable 4 Change in Various Echo Parameters
Change in Echo Parameters Pre-Ablation
 EF 26.2 5.5
 LVEDD 6.83 0.83
 LVESD 5.83 0.55
 LVESV 178 72
 LVEDV 242 85
Values are mean  SD.
Abbreviations as in Tables 1 and 2.
Change in Echo Parameters After Ablation Stratified by PercentageTable 5 Change in Echo Parameters After Ablation Stratified b
 in Echo
Parameters
Pre-Ablation PVC Burden
10% to 20%, n  27 20.1% to 30%, n  20
 EF, pre-ablation 3.11 3.54 5.60 2.64
 LVEDD, cm 0.20 0.17 0.23 0.16
 LVESD, cm 0.18 0.18 0.28 0.18
 LVEDV, ml 11.2 12.9 35.5 13.7
 LVESV, ml 17.6 15.6 27.1 9.8
NYHA class 1.000 (1.00 to 0.00) 0.000 (1.00 to 0.00) Values are mean  SD or median (interquartile range). *Kruskal-Wallis test was used for statistical com
NS  not significant; NYHA  New York Heart Association; other abbreviations as in Tables 1 and 2.burden greater than 22% is associated with the greatest
improvement in CRT response as measured by LVEF, LV
dimensions, and NYHA class; and 5) the benefits of PVC
ablation are largely related to an increase in effective BiV
pacing. The current results constitute the first evidence that
improved CRT response can be achieved through RFA of
PVC in nonresponders with a high PVC burden.
Frequent PVC and LV dysfunction. The precise preva-
lence of high PVC burden in the general population and in
those with LV dysfunction remains unknown. In the cur-
rent study, 13% of subjects with known cardiomyopathy and
wide QRS who were nonresponders to CRT had a signif-
icant PVC burden ( 10,000 PVCs in 24 h). Frequent
idiopathic PVC may be benign from a sudden cardiac death
standpoint, but may result in a reversible form of LV
dysfunction (30,31). PVC can not only cause LV dysfunc-
tion in patients with no underlying structural heart disease,
but they can also worsen LV function in those with known
cardiomyopathy and underlying scar (32,33). However, the
pathophysiology behind PVC-mediated cardiomyopathy is
unclear. Possible mechanisms include dysynchronous ven-
tricular activation, impaired calcium handling, or a decrease
in calcium transient (34,35). Even in patients with under-
lying structural heart disease and cardiomyopathy with
frequent PVC, the LV dysfunction may be partially revers-
ible if the PVC can be abated. Indeed, several studies have
shown that abatement of frequent PVC through RFA may
result in significant improvement and sometimes normal-
PVC Ablationore and After PVC Ablation
t-Ablation Mean Improvement p Value
.7 6.7 6.42 5.26 0.001
1 0.91 0.32 0.26 0.001
2 0.32 0.31 0.23 0.001
5 23 33.17 22.94 0.001
2 63 30.65 21.63 0.001
VC Burdencentage of PVC Burden
1-Way ANOVA
p Value Bonferroni Post-Hoc Testing30%, n  18
2.28 4.75 0.001 3 differs from 1, 2 (0.001)
1 differs from 2 (0.05)
0.62 0.20 0.001 3 differs from 1, 2 (0.001)
1 does not differ from 2 (NS)
0.55 0.17 0.001 3 differs from 1, 2 (0.001)
1 does not differ from 2 (NS)
54.5 8.1 0.001 All differ from each other (0.001)
63.3 10.8 0.001 3 differs from 1, 2 (0.001)
1 differs from 2 (0.05)
0 (1.00 to0.75) 0.062*AfterBef
Pos
32
6.5
5.6
14
21of Py Per
>
1




1.00parisons.
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and without baseline LV dysfunction (30,32,33).
CRT nonresponse and PVC ablation. It has now become
apparent that 25% to 30% of patients with drug refractory
LV dysfunction and heart failure will not respond to CRT.
However, the causes for this lack of response remain
unclear. Our study is the first to describe the correlation
between high PVC burden and CRT nonresponse. It has
been shown that patients with a higher percentage of BiV
pacing derive the most benefit from CRT with resultant
gains in LVEF and functional class (36). As is shown by our
results, frequent PVC can reduce the percentage of BiV
pacing, thereby hindering the reverse remodeling and in-
crease substrate changes that promote worsening LV dys-
function. When revascularization, pharmacotherapy, and
CRT optimization options have been exhausted, identifica-
tion and abatement of frequent PVC may offer an excellent
strategy to improve LV function and clinical response in
CRT nonresponders.
Figure 2 Correlation Between PVC Burden
and EF Change Following Ablation
Percentage of pre-ablation premature ventricular contraction (PVC) burden and
correlation with change in post-ablation ejection fraction (EF). The figure shows
a Pearson correlation coefficient of 0.699, which is statistically significant at
p  0.001 (2-tailed). BiV  biventricular.
Improvements in Echo Parameters and NYHA ClassPost-Ablation With Percentag of Pre-Ablation PVCBurden Stra ified to <22% nd >22%
Table 6
Improvements in Echo Parameters nd NYHA Class
Post-Ablation With Percentage of Pre-Ablation PVC
Burden Stratified to <22% and >22%
Change in Echo
Parameters
Pre-Ablation PVC Ablation
Independent
t Test p Value<22.0%, n  33 >22.0%, n  32
 EF 4.79 7.25 12.66 7.54 0.001
 LVEDD 0.18 0.18 0.47 0.24 0.001
 LVESD 0.17 0.19 0.46 0.18 0.001
 LVESV 18.7 15.4 48.1 19.8 0.001
 LVEDV 16.0 17.8 45.8 13.2 0.001
 NYHA class 1.00 (1.00,
0.00)
1.0 (1.00,
0.00)
0.525*
Values are mean  SD and median (interquartile range). *Mann-Whitney U test was used for
tatistical comparisons.
Abbreviations as in Tables 1, 2, and 5.This concept is further supported by the findings in the
subset of 25 patients who had the CRT turned off 1 year
after successful PVC ablation. As shown in Table 7, the
improvement in NYHA class and reverse remodeling evi-
denced by echocardiographic parameters after PVC ablation
in these patients were lost 6 months after the CRT was
turned off. These observations underscore the importance of
CRT as the mechanistic basis of improvement after PVC
ablation. In conjunction with the BiV pacing frequency
data, these results also suggest that PVC ablation renders
these patients responders to BiV pacing.
Factors determining the success of PVC ablation in
improving LV function. Abatement of frequent PVC and
the incremental benefit of increased BiV pacing and myo-
cardial reverse remodeling seem to be 1 of the reasons for
the overall improvement in EF in patients after PVC
ablation. Our data show that the degree of PVC burden and
the pre-ablation BiV pacing percentage are important fac-
tors that determine whether PVC ablation will result in
significant improvement in LV function. In prior studies
(31–33), this number has ranged from 5% to 24%. In a
previous study (31), the presence of LV myocardial scar was
found to be a significant predictor for the improvement of
LV function after a PVC ablation. Our results indicate that
pre-ablation PVC burden greater than 22% is associated
with a statistically significant improvement in LV function
following RFA. Incidentally, all of our patients had struc-
tural heart disease in the form of ischemic or idiopathic
cardiomyopathy with manifest scar on the voltage maps.
Clinical trials on CRT implantation have shown an
absolute increase of 5% in EF in implanted subjects as a
measure of CRT response (37). We elected to use EF
(instead of dysynchrony indices or volume measurements) to
measure response to CRT, because it is the most commonly
Figure 3 Correlation Between Pre-Ablation BIV Pacing %
and Post-Ablation Improvement in EF
The figure shows a Pearson’s correlation coefficient of 0.699 which is sta-
tistically significant at p  0.001 (2-tailed). BIV  biventricular pacinig;
EF  ejection fraction.measured cardiac function by different modalities and its
ing tur
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(38,39). However, our study also showed a significant
decrease in cardiac dimensions following ablation.
Serial Echo Parameters and NYHA Class Before and 6 MonthsAfter Successful PVC Ablation, and 6 Months After BiV Pacing WaTable 7 Serial Echo Parameters nd NYHA Class Bef re and 6After Successful PVC Ablation, and 6 Months After BiV
Echo Parameters
Time Point 1
Pre-Ablation %
(n  25)
Time Point 2
6 Months Post-Ablation
CRT-ON, (n  25)
EF 25.8 5 34.8 4
LVEDD, cm 6.83 0.83 5.23 0.54
LVESD, cm 5.48 0.75 4.78 0.5
LVESV, ml 169 62 152 56
LVEDV, ml 233 55 217 42
Median NYHA class 3 2
Values are mean  SD. Only a subset of patients who improved their EF (delta 0%) had BiV pac
BiV  biventricular; other abbreviations as in Tables 1, 2, 3, and 5.
Shows the Differences Between Post-PVCAblation Responders Versus NonrespondersTable 8 Shows the Differences Betw en Post-PVCAblation Responders Versus Nonresponders
Clinical Variables
Responders
(n  43)
Nonresponders
(n  22) p Value
Age, yrs 66.7 12.1 66.5 13.1 0.969
Sex, M/F 34 (79.1)/9 (20.9) 17 (77.3)/ 5 (22.7) 0.868
Cardiomyopathy 0.328
DCM 26 (60.5) 16 (72.7)
ICM 17 (39.5) 6 (27.3)
NYHA class pre-ablation 0.345
2 6 (14.0) 1 (4.5)
3 33 (76.7) 17 (77.3)
4 4 (9.3) 4 (18.2)
Previous device
ICD 11 (25.6) 6 (27.3) 0.949
PPM 5 (11.6) 2 (9.1)
None 27 (62.8) 14 (63.6)
Device type 0.700
CRTD 40 (93.0) 21 (95.5)
CRTP 3 (7.0) 1 (4.5)
Baseline QRS width 153.2 18.1 159.2 17.1 0.197
History of diabetes 21 (48.8) 13 (59.1) 0.434
History of HTN 26 (60.5) 16 (72.7) 0.328
History of hyperlipidemia 21 (48.6) 17 (77.3) 0.028
History of CAD 22 (51.2) 7 (31.8) 0.138
History of CRI 7 (16.3) 4 (18.2) 0.846
Successful ablation 45/49 (91.8) 24/27 (88.9) 0.878
 LVEDD 0.44 0.22 0.11 0.16 0.001
 LVESD 0.40 0.22 0.13 0.15 0.001
 LVESV 44.1 19.2 11.9 12.0 0.001
 LVEDV 41.0 16.8 10.3 14.5 0.001
Post-ablation EF 35.1 5.5 27.9 6.4 0.001
PVC burden before 28.7 12.2 16.2 5.0 0.001
BiV pacing before 71.3 12.2 83.8 5.0 0.001
BiV pacing after 99.7 0.8 99.8 0.5 0.691
 BiV pacing post-PVC
ablation
28.4 12.1 16.0 4.9 0.001
Values are mean  SD or n (%).
CRI  Chronic renal insufficiency; CRTD  cardiac resynchronization therapy-defibrillator; CRTP cardiac resynchronization therapy-pacemaker; PPM permanent pacemaker; other abbreviations
as in Tables 1, 5, and 7.Study limitations. The following are the limitations of the
current study. 1) The patients did not have an echo
immediately after the ablation as it may take several days for
PVC abatement to translate into meaningful effect on
reverse remodeling of the LV. 2) The long-term impact of
PVC ablation on CRT response and survival could not be
determined in this study.
The data suggest that most of the benefit from PVC
ablation is probably related to the improved biventricular
pacing. However, in the absence of a control group with
continued high PVC burden and ineffective CRT, we
cannot completely exclude whether tachycardia-mediated
cardiomyopathy plays a role in CRT nonresponse in addi-
tion to the effective BiV pacing. In this respect, the real
long-term time course of response to CRT with regard to
PVC burden is largely unknown. However, it is unlikely
that nonresponders to CRT would experience disappear-
ance of PVC over a longer follow-up as the average time
from CRT implant to PVC ablation was 14.8  6.1
months. Indeed, we believe that patients with continued
high PVC burden even after 1 year following CRT
implant would derive significant clinical benefit from
PVC abatement through ablation. Incidentally, 34% of
patients who had successful PVC ablation resulting in
more than 99% BiVpacing continued to be nonre-
sponders. However, this group reflects the patients with
lower PVC burden.
Conclusions
Frequent PVCs are a less common but important and
treatable cause of nonresponse to CRT. Successful RFA of
PVC foci improves LV function and NYHA class and
promotes reverse remodeling in CRT nonresponders. Thus,
PVC ablation may be used to enhance CRT efficacy in
nonresponders with significant PVC burden.
Reprint requests and correspondence: Dr. Dhanunjaya Lak-
kireddy, Center for Excellence in Atrial Fibrillation/Complex
Arrhythmia Management, Bloch Heart Rhythm Center at Uni-
versity of Kansas Hospital, 3901 Rainbow Boulevard, MS 4023,
ned Offhs
ing Was Turned Off
Time Point 3
1-Year Post-Ablation
CRT-OFF (n  25)
p Value From Paired Comparison
1 vs. 2 1 vs. 3 2 vs. 3
24.9 6 0.001 0.707 0.001
7.28 1 0.013 0.098 0.001
6.10 0.95 0.006 0.072 0.001
187 58 0.373 0.310 0.013
241 85 0.259 0.241 0.006
3 0.001 0.948 0.001
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